Livzon Pharmaceutical Group: China NMPA Accepts Lecankitug Injection NDA – Major Milestone for Innovative AS Treatment
Key Highlights
- Livzon Pharmaceutical Group’s subsidiary, Livzon MABPharm Inc. (“Livzon MAB”), has received formal acceptance from China’s National Medical Products Administration (NMPA) for the marketing authorization application of Lecankitug Injection.
- Lecankitug Injection is jointly developed with Beijing Xinkanghe Biopharmaceutical Technology Co., Ltd.
- The drug targets adult patients with active ankylosing spondylitis (AS) who have not responded adequately or are intolerant to conventional treatments.
- This is the second indication for Lecankitug Injection, following its application for psoriasis, which was included in the Priority Review pathway.
- Supported by a pivotal Phase III multi-center, randomized, double-blind, placebo-controlled study, the drug demonstrated rapid, robust, and sustained efficacy, with advantages in rapid onset, symptom relief, and quality of life improvement.
- The drug is administered via subcutaneous injection every 4 weeks, with a favorable safety profile and applicability to both TNF inhibitor-naïve and -experienced patients.
- To date, RMB 216.9 million has been invested in the development of Lecankitug Injection.
- Lecankitug Injection could become the first domestically-developed IL-17A/F dual-target drug approved for AS in China, where currently only one imported product (bimekizumab) has this indication.
In-Depth Details for Investors
Drug and Indication Overview
Lecankitug Injection (萊康奇塔單抗注射液) is a locally developed Class 1 therapeutic biological product designed for adult patients with active ankylosing spondylitis (AS), a chronic inflammatory and immune-mediated rheumatic disease affecting an estimated 4 million people in China. This patient population represents a significant unmet medical need, especially for those unresponsive or intolerant to conventional therapies.
The application for Lecankitug Injection builds on a robust clinical foundation, including a pivotal Phase III study. The drug demonstrated:
- Rapid onset of efficacy, with measurable improvements as early as one week after initiation.
- Deep and sustained symptom relief, with significant clinical response at 16 weeks compared to placebo and stable benefits up to 52 weeks, including in patients switching to Lecankitug.
- Improvements in quality of life and inflammatory markers.
- Favorable safety and tolerability, with adverse event rates comparable to placebo and no new safety signals.
- Broad applicability across both TNF inhibitor-naïve and TNFi-experienced patients.
The drug is administered as a subcutaneous injection every 4 weeks (160mg/1.6mL per vial), supporting convenient dosing and potentially improving patient adherence.
Market Potential and Competitive Landscape
The competitive advantage for Lecankitug Injection is substantial. As of the announcement date, only one IL-17A/F dual-target imported drug, bimekizumab, is approved in China for AS. No domestically-developed drug with this mechanism has yet received approval for AS, positioning Lecankitug as a potential first-in-class local product. This could translate into significant market opportunity for Livzon MAB and its parent, Livzon Pharmaceutical Group.
The successful commercialization of Lecankitug Injection would allow Livzon to capture a share of the large and fast-growing AS biologics market, especially with increasing demand for innovative homegrown therapies in China.
Financial Impact and Risk Factors
To date, the cumulative direct investment in R&D for Lecankitug Injection totals approximately RMB 216.9 million, underscoring the company’s commitment to innovation. While the acceptance of the NDA is a significant de-risking event, investors should be aware that final approval from the NMPA is still subject to regulatory review and there remain uncertainties in terms of timing and outcome.
Importantly, the company notes that receipt of the Acceptance Notice will not have an immediate material impact on near-term financial results. Investors should monitor further disclosures as the review progresses, as eventual approval and launch could be highly accretive to Livzon’s revenues and earnings.
Governance and Management
The announcement was authorized by the Board, led by Chairman Zhu Baoguo. The executive team includes President Liu Daping and Vice Chairman Tang Yanggang, with a robust independent and employee representative director presence, reflecting a diversified and experienced leadership structure.
What Shareholders Should Know
- The acceptance of Lecankitug Injection’s NDA for AS is a major milestone that could significantly impact Livzon’s future revenues and market position if approved.
- Lecankitug Injection, if approved, would be the first homegrown IL-17A/F dual-target biologic for AS in China, opening a large and currently under-served market segment.
- The company has invested heavily in R&D, signaling strong commitment to innovative biologics.
- Investors should remain cautious as regulatory approval is pending, with inherent timing and outcome risks.
- Further material news is expected as the review advances. These developments may be price-sensitive and could move the company’s share price upon positive or negative outcomes.
Disclaimer
This article is provided for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult professional advisors before making investment decisions. The outcome and timing of the regulatory review process for Lecankitug Injection remain uncertain and may materially affect the company’s financial performance and share price.
麗珠醫藥集團：萊康奇塔單抗注射液新藥上市申請獲中國藥監局受理——投資者必讀詳情
重點摘要
- 麗珠醫藥集團子公司麗珠單抗收到中國國家藥品監督管理局（NMPA）正式受理萊康奇塔單抗注射液（Lecankitug Injection）上市許可申請。
- 該藥由麗珠單抗與北京鑫康合生物醫藥科技有限公司共同研發。
- 適應症針對因傳統治療無效或不耐受的活動性強直性脊柱炎（AS）成年患者。
- 這是萊康奇塔單抗的第二個適應症申請，首個申請為銀屑病並已納入優先審評。
- 關鍵Ⅲ期多中心、隨機、雙盲、安慰劑對照臨床試驗證明該藥具有起效快、療效穩定、症狀改善明顯、生活質量提升等多項優勢。
- 每四週皮下注射一次，安全性良好，對TNFi新手及既往使用者皆有效。
- 研發累計投入約2.169億元人民幣。
- 若獲批，將成為中國首個自主研發IL-17A/F雙靶點強直性脊柱炎生物藥，目前僅有一款進口產品（bimekizumab）獲批該適應症。
投資者詳細關注點
藥物及適應症詳情
萊康奇塔單抗注射液為國產創新一類治療性生物製品，主攻中國約400萬強直性脊柱炎患者的治療空白。目標群體為對傳統療法無效或不耐受的成年AS患者，臨床需求巨大。
關鍵臨床數據顯示：
- 起效迅速，一週內即可見明顯改善。
- 症狀緩解深度大且持續，16週臨床反應明顯優於安慰劑，52週仍穩定，轉藥患者同樣受益。
- 炎症標誌物及生活質量同步改善。
- 安全性良好，不良事件發生率與安慰劑組近似，無新安全信號。
- TNFi新手及既往用藥者均適用，療效穩定一致。
藥品規格為160mg/1.6mL/瓶，每四週皮下注射一次，服藥便捷有助提升依從性。
市場潛力及競爭格局
截至公告日，國內僅有bimekizumab這一進口IL-17A/F雙靶點藥物獲批AS適應症，國產產品尚屬空白。萊康奇塔單抗若成功上市，將成為中國首個本土同類創新生物藥，市場潛力巨大，有望搶佔生物藥增長新高地。
國產創新藥的推進亦契合國家政策導向，有助公司在國內高端生物藥市場形成競爭優勢。
財務影響及風險提示
項目研發累計直接投入約2.169億元人民幣，充分展現公司創新決心。雖然NDA受理大幅降低項目風險，但最終審批尚待NMPA進一步審查，時間及結果存在不確定性。
公司明確表示，本次受理對近期業績暫不產生實質影響。投資者應密切跟進後續進展，隨著藥品審評推進，若獲批上市，將對收入及盈利有明顯增厚，屬於高度潛在價值事件。
公司治理與管理層
公告由董事會授權發布，董事長朱保國領銜，管理團隊多元，具備豐富醫藥及資本市場經驗。
股東須知
- 本次NDA受理為公司創新藥業務重大里程碑，未來若獲批上市，或將顯著提升收入、利潤及行業競爭地位。
- 萊康奇塔單抗有望成為國產首個IL-17A/F雙靶點AS生物藥，對國內創新藥市場格局具突破意義。
- 公司對創新研發持續重倉，專案進展值得持續關注。
- 審批過程仍存不確定性，投資需審慎。
- 未來若有重大進展將形成敏感消息，股價或將隨之波動。
免責聲明
本文僅供信息參考，不構成投資建議。投資者應自行研究並諮詢專業顧問，謹慎決策。藥品最終審批及上市時間尚存不確定性，對公司財務及股價或產生重大影響。
